Page 7 - Pascal Touchon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Primary Endpoint of Confirmed Disability Improvement at 12 Months Not Achieved Company to Further Analyze Data and Evaluate Strategic Options for ATA188 Program with Focusing of Resources and.

United statesPascal touchonPierre fabreAtara biotherapeutics incExchange commissionSecurities exchangeChief executive officerBiologics license applicationSecurities actSecurities exchange actPierre fabre laboratoriesMiddle eastSouthern californiaFinancial condition

Atara Biotherapeutics, Inc (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript November 4, 2023 Operator: Good morning, and thank you for standing by. Welcome to Atara Biotherapeutics’ Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s call is being recorded. I would now like to hand the call over to Alex Chapman, […]

Mid cap dividend stocks to buyPierre fabreAtara biotherapeuticsAlex chapmanPascal touchonAutoimmune disease

Atara Biotherapeutics, Inc (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript

Operator: Good morning, and thank you for standing by. Welcome to Atara Biotherapeutics’ Third Quarter 2023 Financial Results Conference Call.

Canaccord genuitySalim syedPierre fabreAlex chapmanJohn newmanPascal touchonEric hyllengrenCorporate communicationsAtara biotherapeutics incCall transcript novemberResults conferenceVice presidentInvestor relationsPierre fabre laboratoriesChief executive officerChief financial

Pierre Fabre Laboratories to accelerate their development in onco-hematology by acquiring the license for a breakthrough T-cell immunotherapy in North America

/PRNewswire/ Pierre Fabre Laboratories announced today an expanded global partnership with Atara Biotherapeutics, a leader in T-cell immunotherapy,.

Midi pyréesUnited statesLaure sgandurraPrnewswire pierreEric ducournauPascal touchonPierre fabrePierre fabre foundationEarly access programPierre fabre laboratoriesAll remainingFabre laboratoriesTake over all manufacturingRegulatory activitiesFollowing transitionChief executive officer

Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at StockNews com

Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at StockNews com
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United statesPascal touchonAtara biotherapeutics incLazard asset managementRoyal bankAtara biotherapeutics company profilePrincipal financial group incMillennium managementGet free reportFinancial groupAsset management